- Acquisition
- up to €700M (Ipsen)
Memo Therapeutics is a Swiss biotech developing potravitug, a Phase II antibody against BK polyomavirus infection in kidney-transplant patients. In July 2026 Ipsen agreed to acquire it for up to €700 million, with €200 million paid at closing and the rest tied to milestones — an exit path illustrating how Swiss biotech increasingly exits through acquisition by larger European pharma rather than IPO.